Coffee Creamer Recalled as FDA Sets Highest Risk Level
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
A nondairy coffee creamer sold across the Northeast has been recalled after it was found that it could pose serious health risks to consumers with milk allergies.
MO-CHA brand Premium Non-Dairy Creamer, imported by Momo Tea Inc. of Maspeth, New York, was voluntarily recalled after it was found to contain undeclared milk ingredients.
On Tuesday, the Food and Drug Administration (FDA) classified the recall as Class I, its most serious designation.
Newsweek has contacted Momo Tea Inc via social media for comment.
Why It Matters
Federal food labeling regulations require that all major allergens, including milk, be clearly disclosed on packaging. The recalled product includes milk-derived ingredients, whey powder and casein, but does not declare milk as an allergen on its label.
This type of labeling omission can be life-threatening for individuals with milk allergies as food allergy symptoms can include hives, rashes, vomiting, diarrhea, stomach cramps, respiratory issues and, in severe cases, anaphylaxis—a condition marked by throat swelling, a drop in blood pressure, difficulty breathing and loss of consciousness.
File photo: milk being poured into a mug of coffee.
File photo: milk being poured into a mug of coffee.
Agencia el Universal/GDA via AP
What To Know
The affected product, which was imported from China and packaged in 2.2-pound bags, has a shelf life of two years.
There are no lot codes or unique identifiers listed in the recall notice. According to the FDA, all units of the product on the market are subject to the recall, with about 4,500 cases distributed across New York, New Jersey and Connecticut.
Momo Tea Inc. initiated the recall on April 10, and the FDA released its classification on April 22.
FDA's classification indicates a reasonable probability that consumption could cause severe health consequences or death, as a Class I recall determines "a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death."
Ingredients listed on the product label include glucose syrup, refined vegetable oil, whey powder, sugar and various food additives.
What People Are Saying
Dr. Sebastian Lighvani, the director of New York Allergy & Asthma PLLC, previously told Newsweek: "Every three minutes in the United States, someone ends up in an emergency room because of an allergic reaction after accidental ingestion of food. So even when we try hard, these reactions are happening. And if you look at the incidence of anaphylaxis, it has skyrocketed in the last 5, 10, 20 years. And in the U.S., there's like a 300 to 400 percent increase in the rates of anaphylaxis to foods."
What Happens Next
According to the FDA's notice, the recall is still ongoing.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Recall alert: Over 19,000 cans of Dr Pepper Zero Sugar recalled for containing sugar
Over 19,000 cases of Dr Pepper Zero Sugar are being recalled after the cans were found to contain full-sugar soda, the U.S. Food and Drug Administration announced. The voluntary recall issued on May 23 affects the 12-ounce aluminum cans of a 12-pack and 24-pack case of Dr Pepper Zero Sugar. 'Product labeled to be zero sugar contains full sugar product,' the FDA wrote about the drink. The recalled product contains the same amount of sugar found in regular Dr Pepper, which is 39 grams per can. The recalled cans have the product code XXXXRS05165 with a 'best by' date of February 16, 2026. The cans were made by Pepsi Beverages Company in Jacksonville, Florida and distributed to only Florida, Georgia and South Carolina. On June 5, the FDA then classified the product as a class II recall. This level of recall is 'a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote,' according to the FDA. See the full recall here. Recall alert: These window air conditioners could cause mold exposure Recall alert: Bring these crackers back to the store due to undeclared allergen Recall alert: Throw away these 17 salads, salsas due to salmonella concern Read the original article on MassLive.
Yahoo
2 hours ago
- Yahoo
Parents are dismayed after FDA rejects experimental drug 4-year-old girl relies on
A family thought they had a life-changing drug for their 4-year-old daughter. Then the FDA rejected it. Channel 2's Michael Doudna heard from the girl's parents. For Hope Filchak, her daily routine includes a daily shot to help provide a normal life. However, soon the drug may go away. 'It's scary to think she might not have this in just a few months,' Caroline Filchak, Hope's mother, said. [DOWNLOAD: Free WSB-TV News app for alerts as news breaks] Hope was born with a rare mitochondrial disease that impacts fewer than 100 people in the world. The impacts are wide-ranging and a challenge to overcome. 'From early on, it was an uphill battle for Hope,' Caroline Filchak said. 'I think she's got 12 specialists that we see in three different states.' 'It affects her brain, her heart, her eyes and her ears, deafness, blindness, and then two heart defects,' Ben Filchak, Hope's father, said. There are no FDA-approved drugs for Hope's condition. So when heart troubles arose in 2024, the family was forced to turn to an experimental drug, elemipretide, and saw immediate improvement. 'Her energy increased, and her heart function has stabilized completely,' Ben Fiilchak said. However, last month, the FDA declined to give it approval. 'I would say that the FDA is trying to regulate two things, right. They're trying to make sure the products are safe, including drugs, but also that they are efficacious for people,' said Rossana Sanchez Russo, an Emory clinical geneticist. According to the parent company producing the drug, the FDA's rejection was in part because the FDA did not see an improvement in a six-minute walk test. 'We all know in the field that a six-minute walk test is not the be-all end-all outcome measure for mitochondrial diseases,' Amy Goldstein, a leading mitochondrial disease expert, said. She says the drug showed improvement in areas such as quality of life and cardiac health. 'I myself personally saved a baby in my cardiac ICU with Barre syndrome. He went home with no cardiac manifestations after arriving here in severe heart failure and needing a heart transplant,' Goldstein said. 'We were extremely disappointed that based on all of the data, they made the decision not to approve the drug.' Another hurdle rare disease drug testing faces is sample size. By its very nature, only a few people have these diseases, so getting a meaningful sample during clinical trials can be difficult. 'Sometimes we don't have enough burden of proof to be able to formally say that. That doesn't mean that it may not be working for a family or that it might not work for other conditions. It may mean that we just do not have all the data,' Sanchez Russo said. The FDA says the company behind the drug can reapply for approval, but it is unclear if it will be successful and how long the company can stay committed to producing a drug without the FDA giving an OK. Hope's family has a four-month supply of the drug left. However, they do not know how much longer access to the medicine will last. 'Hope is a special little girl, and she means so much to our family,' Caroline Filchak said. TRENDING STORIES: Raids uncover largest fentanyl pill operation in state history in Atlanta, Douglasville Hurricane season starts quietly in the Atlantic They were once best friends, then one killed the other. We take you inside this bizarre murder case [SIGN UP: WSB-TV Daily Headlines Newsletter]
Yahoo
2 hours ago
- Yahoo
Roughly 20,000 Cases of Popular Soda Have Been Recalled
Nearly 20,000 cases of soda were recalled by the U.S. Food & Drug Administration due to misleading labels. On May 23, the U.S. Food & Drug Administration initiated a recall for 19,203 cases of Dr Pepper Zero Sugar. Although they labeled as "zero sugar," the cans in these 12-pack and 24-pack cases actually contained full sugar. A regular 12-ounce can of Dr Pepper contains 39 grams of sugar. That'd be unsafe to drink if you're diabetic. The FDA ruled this a Class II recall, which means the produce could cause "temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." The cases of Dr Pepper that were recalled by the FDA were found in Florida, Georgia and South Carolina. At this time, no other Dr Pepper products were impacted by the FDA's Class II recall. The FDA states that recalled products can often be returned to where they were originally purchased. However, that's not always the case. "A medical device recall does not always mean that you must stop using the product or return it to the company. A recall sometimes means that the medical device needs to be checked, adjusted, or fixed. Contact your health care provider for additional guidance," the FDA's guidelines state. "If you cannot return a product, dispose of the product properly. If it's contaminated, ensure it is in a secure container and place the item in a covered trash can or dumpster so no people or animals can access it. Be sure to follow your local disposal laws." Roughly 20,000 Cases of Popular Soda Have Been Recalled first appeared on Men's Journal on Jun 10, 2025
